Journal of Yeungnam Medical Science

영남대 의대 학술지 편집위원회 (Yeungnam University College of Medicine, Yeungnam University Institute Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Association between fatty liver disease and hearing impairment in Korean adults: a retrospective cross-sectional study

  • Da Jung Jung (Department of Otorhinolaryngology-Head and Neck Surgery, Kyungpook National University Hospital, School of Medicine, Kyungpook National University)
  • 투고 : 2023.03.27
  • 심사 : 2023.05.11
  • 발행 : 2023.10.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: We hypothesized that fatty liver disease (FLD) is associated with a high prevalence of hearing loss (HL) owing to metabolic disturbances. This study aimed to evaluate the association between FLD and HL in a large sample of the Korean population. Methods: We used a dataset of adults who underwent routine voluntary health checkups (n=21,316). Fatty liver index (FLI) was calculated using Bedogni's equation. The patients were divided into two groups: the non-FLD (NFLD) group (n=18,518, FLI <60) and the FLD group (n=2,798, FLI ≥60). Hearing thresholds were measured using an automatic audiometer. The average hearing threshold (AHT) was calculated as the pure-tone average at four frequencies (0.5, 1, 2, and 3 kHz). HL was defined as an AHT of >40 dB. Results: HL was observed in 1,370 (7.4%) and 238 patients (8.5%) in the NFLD and FLD groups, respectively (p=0.041). Compared with the NFLD group, the odds ratio for HL in the FLD group was 1.16 (p=0.040) and 1.46 (p<0.001) in univariate and multivariate logistic regression analyses, respectively. Linear regression analyses revealed that FLI was positively associated with AHT in both univariate and multivariate analyses. Analyses using a propensity score-matched cohort showed trends similar to those using the total cohort. Conclusion: FLD and FLI were associated with poor hearing thresholds and HL. Therefore, active monitoring of hearing impairment in patients with FLD may be helpful for early diagnosis and treatment of HL in the general population.

키워드

과제정보

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant No: HR22C1832).

참고문헌

  1. World Health Organization (WHO). Deafness and hearing loss [Internet]. Geneva: WHO; 2023 [cited 2023 Jan 18]. https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss/. 
  2. Przewozny T, Gojska-Grymajlo A, Kwar ciany M, Gasecki D , Narkiewicz K. Hypertension and cochlear hearing loss. Blood Press 2015;24:199-205.  https://doi.org/10.3109/08037051.2015.1049466
  3. Kang SH, Jung DJ, Choi EW, Park JW, Cho KH, Lee KY, et al. Visceral fat area determined using bioimpedance analysis is associated with hearing loss. Int J Med Sci 2015;12:946-51.  https://doi.org/10.7150/ijms.13184
  4. Kang SH, Jung DJ, Cho KH, Park JW, Lee KY, Do JY. Association between HbA1c level and hearing impairment in a nondiabetic adult population. Metab Syndr Relat Disord 2016;14:129-34.  https://doi.org/10.1089/met.2015.0092
  5. Rim HS, Kim MG, Park DC, Kim SS, Kang DW, Kim SH, et al. Association of metabolic syndrome with sensorineural hearing loss. J Clin Med 2021;10:4866. 
  6. Samocha-Bonet D, Wu B, Ryugo DK. Diabetes mellitus and hearing loss: a review. Ageing Res Rev 2021;71:101423. 
  7. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol 2015;13:2062-70.  https://doi.org/10.1016/j.cgh.2015.07.029
  8. Chalasani N, Deeg MA, Persohn S, Crabb DW. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:1849-55.  https://doi.org/10.1111/j.1572-0241.2003.07619.x
  9. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-16.  https://doi.org/10.1053/jhep.2003.50132
  10. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007;30:2940-4.  https://doi.org/10.2337/dc07-0792
  11. Chen Z, Yu R, Xiong Y, Du F, Zhu S. A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis 2017;16:203. 
  12. Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. Medicine (Baltimore) 2017;96:e8179. 
  13. Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019;71:793-801.  https://doi.org/10.1016/j.jhep.2019.06.021
  14. Kang SH, Cho KH, Do JY. Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. Int J Med Sci 2019;16:285-91.  https://doi.org/10.7150/ijms.28264
  15. Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications. Int J Mol Sci 2022;23:13320. 
  16. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33. 
  17. Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009;49:1537-44.  https://doi.org/10.1002/hep.22845
  18. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202-9.  https://doi.org/10.1016/j.jhep.2020.03.039
  19. Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, et al. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One 2014;9:e107584. 
  20. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005;4:10. 
  21. Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009;137:865-72.  https://doi.org/10.1053/j.gastro.2009.06.005
  22. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 2010;42:503-8.  https://doi.org/10.1016/j.dld.2009.08.002
  23. Long MT, Pedley A, Colantonio LD, Massaro JM, Hoffmann U, Muntner P, et al. Development and validation of the Framingham steatosis index to identify persons with hepatic steatosis. Clin Gastroenterol Hepatol 2016;14:1172-80.  https://doi.org/10.1016/j.cgh.2016.03.034
  24. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-54.  https://doi.org/10.1002/hep.21496
  25. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6.  https://doi.org/10.1002/hep.21669
  26. Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population- based study. Clin Gastroenterol Hepatol 2013;11:1201-4.  https://doi.org/10.1016/j.cgh.2012.12.031
  27. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011;54:145-52.  https://doi.org/10.1002/hep.24356
  28. Kim JH, Kwon SY, Lee SW, Lee CH. Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population. Liver Int 2011;31:1600-1.  https://doi.org/10.1111/j.1478-3231.2011.02580.x
  29. Huang X, Xu M, Chen Y, Peng K, Huang Y, Wang P, et al. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine (Baltimore) 2015;94:e1682. 
  30. Kim SY, Kim HJ. Trends in alcohol consumption for Korean adults from 1998 to 2018: Korea National Health and Nutritional Examination Survey. Nutrients 2021;13:609. 
  31. Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol 2013;28(Suppl 1):11-7.  https://doi.org/10.1111/jgh.12036